CD160 and cancer: In addition, increased CD47 was positively correlated with BTLA, ICOS, CD40LG, CTLA4, CD48, CD28, CD200R1, HAVCR2, CD80, PDCD1(PD-1), CD160, IDO1, HHLA2, CD40, TNFSF15, TIGIT, CD274(PD-L1), CD86, CD44, and TNFRSF9 across 33 cancers (Fig. 6).